“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Pharmaceutical economics & health policy

Pharmaceutical economics & health policy Editorial Comment In this issue, readers will find four original research articles and an in-journal supplement featuring three podium presentations from the first annual international meeting of the Association for Pharmacoeconomics and Outcomes Research held in Philadelphia, Pennsylvania, May 12-15, 1996. The “Pharmaceutical Economics & Health Policy” section is pleased to provide timely coverage of international conferences that focus on the economic appraisal, regulatory oversight, and patient outcomes involving pharmacotherapy. In the first of four original research articles, Dr. Yawn and coworkers (p. 877) present a cost-of-illness model for the treatment of otitis media, including direct and indirect expenditures. Health-related quality-of-life instrumentation as applied to end-stage renal disease is reviewed by Dr. Edge11 and associates (p. 887). Contributions to the medical literature are evaluated in terms of comprehensiveness, reliability, and validity. Dr. Marchetti and colleagues (p. 953) assess adverse events and financial outcomes with the use of fosphenytoin versus phenytoin in hospitalized patients with seizures. Finally, Dr. Thomas and associates (p. 939) present a retrospective health service utilization review of patients prescribed nedocromil sodium for the treatment of asthma. I trust the readership will find these articles to be of interest and value. David Alexander Section Editor Sclar, BPharm, PhD http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Therapeutics Elsevier

Loading next page...
1 Page
 
/lp/elsevier/pharmaceutical-economics-health-policy-XyBFNp2CzF

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.